Biologic therapy was associated with more than seven times greater odds of reaching sustained remission compared with ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

Among patients with systemic autoimmune rheumatic diseases, hospitalization due to COVID-19 was more than twice as likely in ...

Long-term glucocorticoid (GC) use among older adults with late-onset rheumatoid arthritis (LORA) remains prevalent, despite its known adverse effects, according to study results published in ACR Open ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Among patients with systemic autoimmune rheumatic diseases, hospitalization due to COVID-19 was more than twice as likely in those using glucocorticoids ... antirheumatic drugs for the treatment ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Anant is suffering from a disease called Cushing's syndrome. Let's know what this disease is and what kind of problems it ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...